Scarica l'app Stockscreener
10.00
2.25%
-0.23
Dopo l'orario di chiusura:
10.00
Precedente Chiudi:
$10.23
Aprire:
$9.94
Volume 24 ore:
213.96K
Relative Volume:
0.64
Capitalizzazione di mercato:
$569.64M
Reddito:
-
Utile/perdita netta:
$-66.86M
Rapporto P/E:
-8.3333
EPS:
-1.2
Flusso di cassa netto:
$-58.82M
1 W Prestazione:
-5.66%
1M Prestazione:
-3.57%
6M Prestazione:
+67.79%
1 anno Prestazione:
+121.24%
Intervallo 1D:
$9.86
$10.43
Intervallo di 1 settimana:
$9.86
$11.14
Portata 52W:
$2.60
$11.14
Design Therapeutics Inc Stock (DSGN) Company Profile
Nome
Design Therapeutics Inc
Settore
Industria
Telefono
858-293-4900
Indirizzo
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.00 | 582.74M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Iniziato | Craig Hallum | Buy |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-05-04 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-06-10 | Iniziato | Wedbush | Outperform |
| 2022-05-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-19 | Iniziato | Goldman | Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-20 | Iniziato | Piper Sandler | Overweight |
| 2021-04-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - Defense World
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - Barchart.com
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - MarketBeat
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts - TradingView
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year HighWhat's Next? - MarketBeat
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED - PR Newswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - The Manila Times
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials - Business Wire
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00 - Defense World
Ideas Watch: Can Design Therapeutics Inc expand its profit margins2025 Trading Recap & Capital Protection Trade Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
RSI Check: Is Trinseo PLC a potential multi baggerBond Market & Breakout Confirmation Alerts - baoquankhu1.vn
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
Biotech Design Therapeutics to brief investors at two healthcare events - Stock Titan
Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 14.0% - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Design Therapeutics Inc. stock recover after earningsJuly 2025 Sentiment & Fast Exit and Entry Trade Guides - mfd.ru
Design Therapeutics (NASDAQ:DSGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Is Design Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Earnings & Verified Chart Pattern Signals - mfd.ru
Trading Action: What is the long term forecast for Design Therapeutics Inc stockDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Retail Surge: Is Design Therapeutics Inc attractive for institutional investorsJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery - Business Wire
Design Therapeutics Approaches Key Clinical Milestones with Ample Funding - AD HOC NEWS
Published on: 2026-02-07 15:17:14 - baoquankhu1.vn
Is Design Therapeutics Inc. stock near bottom after decline2025 Market WrapUp & AI Powered Buy/Sell Recommendations - mfd.ru
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why - Defense World
Published on: 2026-02-01 06:18:16 - baoquankhu1.vn
Design Therapeutics announces governance-driven board resignation - The Globe and Mail
How volatile is Design Therapeutics Inc. stock2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Loss Report: How volatile is Design Therapeutics Inc stockEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
Design Therapeutics, Inc. Announces Resignation of Deepa Prasad from the Company's Board of Directors, Effective February 1, 2026 - marketscreener.com
Design Therapeutics (NASDAQ:DSGN) Shares Gap UpStill a Buy? - MarketBeat
Recap Report: Does Design Therapeutics Inc meet Warren Buffetts criteria2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Insider Sell: Can Design Therapeutics Inc expand its profit marginsBond Market & AI Enhanced Trading Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Bear Alert: Is Design Therapeutics Inc attractive for institutional investorsTrade Performance Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics - BioSpace
Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Business Wire
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Yahoo Finance
Design Therapeutics (NASDAQ:DSGN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Trading Recap: Will Bullfrog AI Holdings Inc Equity Warrant stock recover after earningsQuarterly Profit Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighHere's What Happened - MarketBeat
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad - The AI Journal
Fuchs Dystrophy Clinical Trial Outlook: 5+ Companies and 7 Emerging Therapies Reshape the Global Treatment Pipeline, Says DelveInsight - Barchart.com
Fuchs Dystrophy Clinical Trial Outlook: 5+ Companies and 7 - openPR.com
Fuchs Endothelial Corneal Dystrophy Clinical Trial Pipeline - openPR.com
Design Therapeutics Inc Azioni (DSGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.71%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):